Biologic switching in PsA: -Retrospective study on 3,851 PsA pts initiating bDMARDs, 1,848 (48%) switched therapy at least once. -TNFis were the initial therapy. -IL17i were the first switch in both single-switch and multi-switch scenarios. -Subsequent switches: back to TNFi https://t.co/tJDJvPeu9T

• https://x.com/AdelaCastro222/status/1933868029126815893/photo/1

Sacroiliac joint involvement in #Psoriatic_arthritis 🔹️681 patients 🔹️Age 45 🔹️31% MRI-positive sacroiliitis 🔹️29% radiographic sacroiliitis 🔹️AxPsS associated with: peripheral arthritis, dactylitis, nail psoriasis POS0297 #EULAR2025 @RheumNow https://t.co/gKANc6mNZB

• https://x.com/Nellziade/status/1933642111938707519/photo/1

Data from COAST-V study (post hoc) 🔹️Ixekizumab in #axSpA 🔹️Efficacy stratified by CRP level 🔹️Better treatment response in the elevated compared to the normal CRP group OP0699 #EULAR2025 @RheumNow https://t.co/1mVoly3Gws

• https://x.com/Nellziade/status/1933643116529307783/photo/1

Why do people not respond to psoriatic arthritis therapies? #EULAR2025 @RheumNow https://t.co/VGLN0R3TyY

• https://x.com/drdavidliew/status/1933791747634835900/photo/1

What is the difference between difficult to treat, and treatment-refractory? (see these criteria for PsA) Treatment refractory means that co-morbidities, psychosocial issues and other factors have been managed adequately, but inflammation keeps on going #EULAR2025 @RheumNow https://t.co/Fzpf0eiCWY

• https://x.com/drdavidliew/status/1933793898075140152/photo/1

POETYK PsA-1 Deucravacitinib TYK2i RCT Ph 3 ACR 20 DEU 54% vs. 34% PBO wk 16 ACR 50 DEU 23% vs. 14% PBO also significant diff for HAQ-DI PASI 75 SF-36 PCS and MDA Less Rx progression @RheumNow #EULAR2025 LB0001 https://t.co/oRLlHwI4Bh

• https://x.com/AurelieRheumo/status/1933797602711179482/photo/1

EULAR Points to consider for the definition of #D2M #Psoriatic_Arthritis 1️⃣ Failure >= 2 b/tsDMARDs with >=2 different MOA 2️⃣ Perceived as problematic 3️⃣ Evidence of persistent disease (active disease, EMM, inflammation) #EULAR2025 @RheumNow https://t.co/69nFEYntF0

• https://x.com/Nellziade/status/1933803800533340267/photo/1

EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent disease (inflammation is mandatory) + 4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI #EULAR2025 @RheumNow https://t.co/8nx26mWX3C

• https://x.com/Nellziade/status/1933804987077066881/photo/1

Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA: ✅ ACR20: 54% vs 34% (placebo) ✅ Skin, joints, fatigue, QoL 📉 Post hoc: less radiographic progression No new safety signals at W16. LB0001 @RheumNow #EULAR2025

📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA. Also improved QoL, skin, and MSK outcomes. Post hoc: slowed radiographic progression. Well tolerated & no new safety signals @RheumNow #EULAR2025 #LB0001

📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT. ASAS20: 51% vs 9%; ASAS40: 23% vs 3%. Promising app-based intervention comprising individualised exercise, pt education & disease Mx. @RheumNow #EULAR2025 #LB0002

#EULAR2025 Abstr#LB0001 Phase 3 RCT of Deucravacitinib in psoriatic arthritis met endpoints (ACR20) over PBO at Week 16. Prespecified early radiographic was not significant but post-hoc (without imputed data) showed radiographic inhibition @RheumNow https://t.co/ORUBtUWH31

• https://x.com/Yuz6Yusof/status/1933808337579061454/photo/1

Guselkumab in APEX study (PsA, n=1020, biologic-naïve): 🦴 Less joint damage: 0.55 vs 1.35 (placebo) 💪 More responders: 67–68% hit ACR20 on GUS 🛡 Safety: similar to placebo GUS - selective IL-23i - delivers joint protection and symptom relief LB0010 @RheumNow #EULAR2025

APEX study Ph3 RCT Guselkumab In BioNaive active PsA w/ erosions>=2 wk 24 ACR20 GUS Q4W 67% Q8W 68% vs PBO 47% Less Rx progression in both Q4W & Q8W vs. PBO #EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ

• https://x.com/AurelieRheumo/status/1933823405377392865/photo/1

EULAR PtC for definition of #TR Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent dis + 4️⃣ Exclude drivers like comorbidities & psychosocial factors 🔺️Exclude failure due to Side Effets/CI #EULAR2025 @RheumNow https://t.co/ULD2Xe6p6A

• https://x.com/Nellziade/status/1933828120173326821/photo/1